Compare traditional and non-traditional PBMs

Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.

Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.

UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.

UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.

As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.

AMCP leaders say PBM reform, new drug pricing models and AI will shape this week’s Nexus meeting in San Diego.

Ty Gluckman, M.D., says missed lipid tests and clinical inertia, not prior authorization, are now the main barriers to reaching LDL goals.

Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands.